BReD is an on-farm diagnostic tool developed by Newcastle University and Mologic that detects herbicide resistance in black-grass. Using a pregnancy-style lateral flow assay to identify specific biomarker proteins, the device provides results in minutes, allowing farmers to quickly map resistance in their fields and make informed weed management decisions.
The Black-grass REsistance Diagnostic (BReD) is a rapid, portable testing tool developed by Newcastle University in partnership with Mologic Ltd to combat herbicide resistance in agricultural weeds. Specifically designed for on-farm use, this pregnancy-style lateral-flow assay allows farmers and agronomists to identify non-target site resistance (NTSR) in black-grass and other grass weeds. By providing immediate data on resistance levels, the tool enables growers to make informed, precision management decisions, optimize herbicide application, and refine rotational control strategies, helping to mitigate the significant economic losses caused by weed competition in cereal production.
The diagnostic tool functions by detecting the presence of the phi (F) class glutathione transferase (AmGSTF1) protein, a validated biomarker that occurs at high concentrations in black-grass populations that have evolved multiple herbicide resistance.
The technology is at TRL 9. It was launched commercially in June 2018 under the BReD brand following a partnership between Newcastle University and Mologic Ltd. The device has been evaluated through AHDB-sponsored field demonstrations and is available for commercial use as an on-farm diagnostic tool.
Newcastle University is a comprehensive public research university in Newcastle upon Tyne, with broad academic and translational activity. Its city‑centre Newcastle Helix innovation district—developed with Newcastle City Council and Legal & General—co‑locates researchers with companies and hosts national innovation centres to enable fast collaboration. Deep integration with Newcastle upon Tyne Hospitals NHS Foundation Trust, supported by a joint research office, enables streamlined study setup, access to clinical populations, and end‑to‑end clinical translation. Research is backed by competitive funding from UKRI councils, the National Institute for Health and Care Research, major charities, the European Union, and industry. A dedicated technology transfer office supports IP, licensing, spinouts, and knowledge‑transfer partnerships.